Economic Impact of a New Rapid PCR Assay for Detecting Influenza Virus in an Emergency Department and Hospitalized Patients

Marcelo Soto, Laura Sampietro-Colom, Anna Vilella, Efraín Pantoja, María Asenjo, Ruth Arjona, Juan Carlos Hurtado, Antoni Trilla, Míriam José Alvarez-Martínez, Aurea Mira, Jordi Vila, María Angeles Marcos, Marcelo Soto, Laura Sampietro-Colom, Anna Vilella, Efraín Pantoja, María Asenjo, Ruth Arjona, Juan Carlos Hurtado, Antoni Trilla, Míriam José Alvarez-Martínez, Aurea Mira, Jordi Vila, María Angeles Marcos

Abstract

Seasonal influenza causes significant morbidity and mortality and has a substantial economic impact on the healthcare system. The main objective of this study was to compare the cost per patient for a rapid commercial PCR assay (Xpert® Flu) with an in-house real-time PCR test for detecting influenza virus. Community patients with influenza like-illness attending the Emergency Department (ED) as well as hospitalized patients in the Hospital Clínic of Barcelona were included. Costs were evaluated from the perspective of the hospital considering the use of resources directly related to influenza testing and treatment. For the purpose of this study, 366 and 691 patients were tested in 2013 and 2014, respectively. The Xpert® Flu test reduced the mean waiting time for patients in the ED by 9.1 hours and decreased the mean isolation time of hospitalized patients by 23.7 hours. This was associated with a 103€ (or about $113) reduction in the cost per patient tested in the ED and 64€ ($70) per hospitalized patient. Sensitivity analyses showed that Xpert® Flu is likely to be cost-saving in hospitals with different contexts and prices.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Time measures used for the…
Fig 1. Time measures used for the cost analysis.
Fig 2. Incremental cost for Emergency Department…
Fig 2. Incremental cost for Emergency Department patients (Xpert® Flu minus in-house PCR).
Fig 3. Incremental cost for hospitalized patients…
Fig 3. Incremental cost for hospitalized patients (Xpert® Flu minus in-house PCR).

References

    1. WHO. Influenza (Seasonal). In: Fact sheet N°211 [Internet]. 2014 [cited 19 May 2015]. Available:
    1. Schanzer DL, Schwartz B. Impact of seasonal and pandemic influenza on emergency department visits, 2003–2010, Ontario, Canada. Acad Emerg Med. 2013;20: 388–397. 10.1111/acem.12111
    1. Molinari NAM, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: Measuring disease burden and costs. Vaccine. 2007;25: 5086–5096. 10.1016/j.vaccine.2007.03.046
    1. Reed C, Chaves SS, Daily Kirley P, Emerson R, Aragon D, Hancock EB, et al. Estimating Influenza Disease Burden from Population-Based Surveillance Data in the United States. PLoS One. 2015;10: e0118369 10.1371/journal.pone.0118369
    1. Rao S, Nyquist A-C. Respiratory viruses and their impact in healthcare. Curr Opin Infect Dis. 2014;27: 342–347.
    1. Bouscambert M, Valette M, Lina B. Rapid bedside tests for diagnosis, management, and prevention of nosocomial influenza. J Hosp Infect. Elsevier Ltd; 2015;89: 314–318. 10.1016/j.jhin.2014.12.017
    1. Henrickson KJ. Cost-effective use of rapid diagnostic techniques in the treatment and prevention of viral respiratory infections. Pediatr Ann. 2005;34: 24–31.
    1. Mahony JB. Detection of respiratory viruses by molecular methods. Clinical Microbiology Reviews. 2008. pp. 716–747. 10.1128/CMR.00037-07
    1. Marcos M, Ramón S, Antón A, Martinez E, Vilella A, Olivé V, et al. Clinical relevance of mixed respiratory viral infections in adults with influenza A H1N1. Eur Respir J. 2011;38: 739–42. 10.1183/09031936.00168610
    1. Sambol AR, Iwen PC, Pieretti M, Basu S, Levi MH, Gilonske KD, et al. Validation of the Cepheid Xpert Flu A Real Time RT-PCR detection panel for Emergency Use Authorization. J Clin Virol. 2010;48: 234–238. 10.1016/j.jcv.2010.06.001
    1. CDC. Influenza-like illness case definition [Internet]. [cited 18 May 2015]. Available:
    1. CDC. People at high risk of developing Flu related complications [Internet]. [cited 18 May 2015]. Available:
    1. Antón A, López-Iglesias AA, Tórtola T, Ruiz-Camps I, Abrisqueta P, Llopart L, et al. Selection and viral load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised patient during treatment with neuraminidase inhibitors. Diagn Microbiol Infect Dis. 2010;68: 214–219. 10.1016/j.diagmicrobio.2010.08.003
    1. Suwannakarn K, Payungporn S, Chieochansin T, Samransamruajkit R, Amonsin A, Songserm T, et al. Typing (A/B) and subtyping (H1/H3/H5) of influenza A viruses by multiplex real-time RT-PCR assays. J Virol Methods. 2008;152: 25–31. 10.1016/j.jviromet.2008.06.002
    1. Antón A, Marcos MÁ, Martínez MJ, Ramón S, Martínez A, Cardeñosa N, et al. D225G mutation in the hemagglutinin protein found in 3 severe cases of 2009 pandemic influenza A (H1N1) in Spain. Diagn Microbiol Infect Dis. 2010;67: 207–208. 10.1016/j.diagmicrobio.2010.02.002
    1. Cohen J. A coefficient of agreement of nominal scales. Educ Psychol Meas. 1960;20: 37–46. 10.1177/001316446002000104
    1. Cox DR, Oakes D. Analysis of survival data. Chapman and Hall/CRC; 1984. 10.1093/biostatistics/5.3.415
    1. Mcclellan K, Perry CM. OSELTAMIVIR: A Review of its Use in Influenza. Drugs. 2001;61: 263–283.
    1. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed Oxford: Oxford University Press; 2005.
    1. Novak-Weekley S, Marlowe EM, Poulter M, Dwyer D, Speers D, Rawlinson W, et al. Evaluation of the cepheid Xpert flu assay for rapid identification and differentiation of influenza A, influenza A 2009 H1N1, and influenza B viruses. J Clin Microbiol. 2012;50: 1704–1710. 10.1128/JCM.06520-11

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner